Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor Share XCould an FDA inspection scupper CVR deadline for BMS’ liso-cel?https://pharmaphorum.com/news/could-an-fda-inspection-scupper-cvr-deadline-for-bms-liso-cel/
Concerns over BMS and Celgene merger payout as FDA extends drug reviewBristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be Share XConcerns over BMS and Celgene merger payout as FDA extends drug reviewhttps://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/
